این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Journal of Biotechnology، جلد ۲۳، شماره ۲، صفحات ۳۰-۳۹
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Eicosapentaenoic Acid Modulates TGF-β1/Smad3/ILK Pathway to Attenuate Renal Fibrosis: A Biotechnological Approach
چکیده انگلیسی مقاله Background: Renal fibrosis is a key pathological process in chronic kidney disease (CKD), characterized by excessive extracellular matrix (ECM) deposition and epithelial-mesenchymal transition (EMT). Current treatment strategies have limited efficacy, necessitating the exploration of novel therapeutic agents. Eicosapentaenoic acid (EPA), a bioactive marine-derived omega-3 polyunsaturated fatty acid, has shown promise in modulating fibrosis-related signaling pathways.

Objectives: This study investigates the potential of EPA in mitigating renal fibrosis through the regulation of the transforming growth factor-β1 (TGF-β1)/Smad3/ILK pathway and its effects on ECM remodeling and EMT suppression in human kidney epithelial cells.

Methods: Human Kidney-2 (HK-2) cells were subjected to albumin-induced EMT and treated with EPA, either alone or in combination with the β-catenin inhibitor LF3. The expression levels of key EMT markers (E-cadherin, N-cadherin, vimentin), ECM regulators (MMPs and TIMPs), and fibrosis-related signaling molecules (TGF-β1, Smad3, ILK) were assessed using immunofluorescence, ELISA, RT-qPCR, and Western blot analysis.

Results: EPA treatment significantly inhibited EMT by downregulating α-SMA, N-cadherin, vimentin, and active β-catenin while restoring E-cadherin expression (p < 0.05). ECM remodeling was evident through increased MMP-1, MMP-3, and MMP-9 expression and decreased TIMP-1 and TIMP-2 levels. Furthermore, EPA reduced TGF-β1, ILK, and phosphorylated Smad3 protein levels, an effect enhanced by LF3 co-treatment.

Conclusion: EPA exhibits biotechnological potential as a marine-derived antifibrotic agent by targeting the TGF-β1/Smad3/ILK pathway to regulate ECM remodeling and EMT suppression in renal fibrosis. This study provides insights into EPA’s application in medical biotechnology, particularly for CKD management.
کلیدواژه‌های انگلیسی مقاله eicosapentaenoic acid,epithelial-mesenchymal transition,extracellular matrix remodeling,marine biotechnology,renal fibrosis,TGF-β1/Smad3/ILK pathway
نویسندگان مقاله Juan Cao |
Department of Nephrology, Taixing People&#039;s Hospital, Taixing, Jiangsu 225400, China

Zhiqiang Wei |
Department of Nephrology, Taixing People&#039;s Hospital, Taixing, Jiangsu 225400, China

Hao Ding |
Department of Nephrology, Taixing People&#039;s Hospital, Taixing, Jiangsu 225400, China

Haitao Li |
Department of Nephrology, Taixing People&#039;s Hospital, Taixing, Jiangsu 225400, China

Di Yin |
Department of Nephrology, Taixing People&#039;s Hospital, Taixing, Jiangsu 225400, China

نشانی اینترنتی https://www.ijbiotech.com/article_221245_71fe31ad0f1b76bba1f694eab63f9bc7.pdf
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات